Apogee Therapeutics (APGE) Enterprise Value (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Enterprise Value data on file, last reported at -$1.1 billion in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$1.1 billion, down 106.48% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.1 billion (down 106.48% YoY), and the FY2025 annual result was -$730.2 million, down 40.25% from the prior year.
• Enterprise Value fell to -$1.1 billion in Q1 2026 per APGE's latest filing, from -$730.2 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$5.0 million in Q2 2022 and troughed at -$1.1 billion in Q1 2026.
• A 5-year average of -$498.2 million and a median of -$517.0 million in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value plunged 2415.08% in 2023, then surged 37.11% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$151.9 million in 2022, then plunged by 160.36% to -$395.5 million in 2023, then plunged by 31.66% to -$520.7 million in 2024, then sank by 40.25% to -$730.2 million in 2025, then slumped by 45.15% to -$1.1 billion in 2026.
• Business Quant data shows APGE's Enterprise Value at -$1.1 billion in Q1 2026, -$730.2 million in Q4 2025, and -$527.3 million in Q3 2025.